Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) Overview | 6 | 1 |
| ATP synthase (EC 3.6.3.14) is an important enzyme that creates the energy storage molecule adenosine triphosphate (ATP). The majority of cellular energy in the form of adenosine triphosphate (ATP) is synthesized by the ubiquitous F1F0 ATP synthase. Po... | 6 | 1 |
| Therapeutics Development | 7 | 3 |
| H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) Products under Development by Stage of Development | 7 | 1 |
| H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) Products under Development by Therapy Area | 8 | 1 |
| H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) Products under Development by Indication | 9 | 1 |
| H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) Products under Development by Companies | 12 | 2 |
| H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) Products under Development by Universities/Institutes | 14 | 2 |
| H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) Therapeutics Assessment | 16 | 4 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 1 |
| Assessment by Route of Administration | 18 | 1 |
| Assessment by Molecule Type | 19 | 1 |
| H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) Companies Involved in Therapeutics Development | 20 | 2 |
| Johnson &Johnson | 20 | 1 |
| Lycera Corp. | 21 | 1 |
| H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) Drug Profiles | 22 | 10 |
| bedaquiline fumarate Drug Profile | 22 | 4 |
| LYC-30937 Drug Profile | 26 | 2 |
| LYC-51194 Drug Profile | 28 | 1 |
| LYC-51661 Drug Profile | 29 | 1 |
| Small Molecule to Inhibit F0F1-ATP Synthase for Tuberculosis Drug Profile | 30 | 1 |
| TMC-207 Back Up Drug Profile | 31 | 1 |
| H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) Dormant Projects | 32 | 1 |
| H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) Featured News &Press Releases | 33 | 14 |
| Aug 22, 2016: Lycera Announces Initiation of Phase 2 Clinical Trial of LYC-30937-EC in Patients with Ulcerative Colitis | 33 | 1 |
| Jun 06, 2016: Speeding up drug discovery to fight tuberculosis | 34 | 1 |
| Mar 18, 2016: Lycera Announces Presentation of Positive Preclinical Results for Lead Candidate LYC-30937 at the 11th Congress of the European Crohn s and Colitis Organization (ECCO) | 34 | 1 |
| Aug 24, 2015: Janssen s SIRTURO to be commissioned by NHS England for the treatment of multi-drug resistant tuberculosis | 35 | 2 |
| Apr 30, 2015: Lycera Initiates Phase 1 Clinical Trial of LYC-30937, a First-In-Class ATPase Modulator for Inflammatory Bowel Disease | 37 | 1 |
| Nov 06, 2014: Janssen Collaborates for Continued Evaluation of Multidrug-Resistant Tuberculosis Treatment Regimens with SIRTURO (bedaquiline) | 38 | 1 |
| Oct 14, 2014: Bedaquiline Found Effective Against Tuberculosis In Indian Patients: Hinduja Hospital says | 39 | 1 |
| Mar 06, 2014: SIRTURO (bedaquiline) Receives Conditional Approval in the European Union for the Treatment of Multi-Drug Resistant Tuberculosis | 39 | 1 |
| Dec 20, 2013: SIRTURO Receives Positive Opinion from the Committee for MedicinalProducts for Human Use as Part of Combination Therapy to Treat Adults with Pulmonary Multi-Drug Resistant Tuberculosis | 40 | 1 |
| Dec 19, 2013: Pharmstandard announces registration of Sirturo for MDR-TB | 41 | 1 |
| Jun 13, 2013: WHO Issues Interim Guidance On Bedaquiline To Treat Multidrug-Resistant Tuberculosis | 42 | 1 |
| Dec 31, 2012: FDA Grants Accelerated Approval For Sirturo As Part of Combination Therapy To Treat Adults With Pulmonary Multi-drug Resistant Tuberculosis | 42 | 2 |
| Dec 21, 2012: Public Citizen Urges FDA To Reject Accelerated Approval For Possibly Dangerous Anti-Tuberculosis Drug Bedaquiline | 44 | 1 |
| Nov 28, 2012: Janssen Announces FDA Advisory Committee Recommends Accelerated Approval Of Investigational Tuberculosis Treatment Bedaquiline | 45 | 1 |
| Nov 26, 2012: J&J's Tuberculosis Drug Bedaquiline Appears Safe And Well-tolerated, FDA Reviewers Say | 46 | 1 |
| Appendix | 47 | 2 |
| Methodology | 47 | 1 |
| Coverage | 47 | 1 |
| Secondary Research | 47 | 1 |
| Primary Research | 47 | 1 |
| Expert Panel Validation | 47 | 1 |
| Contact Us | 47 | 1 |
| Disclaimer | 48 | 1 |
